PTHS PTHS Prepaid Prescription Drug User Fee Act (PDUFA) fees

Other financials

Revenue$10.9M—

Gross profit$9.2M—

Operating income-$13.1M-614%

Net income-$10.2M-420%

EPS (diluted)-$3.09+3.7%

Cash & equivalents$32.0M+24,250%

Total debt$29.6M—

Total equity$35.1M+937%

Total assets$145.4M+15,855%

Operating cash flow-$13.1M-1,977%

CapEx$194.0K—

Free cash flow-$13.3M-2,008%

Market cap$98.22M+75.4%

Enterprise value$95.89M—

P/S3.6×—

Gross margin79.6%—

Operating margin-157.7%—

Net margin-186.2%—

FCF margin-60.8%—

Return on equity-333.8%—

Debt / equity0.8×—

Current ratio2.8×+2.6×

Reported directly by PTHS in its filing.

Tagged under the XBRL concept pths:PrepaidPrescriptionDrugUserFeeActFeesCurrent.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is PTHS's prepaid prescription drug user fee act (PDUFA) fees?: PTHS (PTHS) reported prepaid prescription drug user fee act (PDUFA) fees of $332K in Q1 2026.